Results 41 to 50 of about 3,389 (131)

Plasmid‐Mediated AmpC Detection in Escherichia coli and Klebsiella pneumoniae: In Vitro Prevalence and In Silico Inhibitor Design

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Objectives This study investigated the prevalence of AmpC beta‐lactamase‐producing Escherichia coli and Klebsiella pneumoniae in clinical specimens collected in Lahore, Pakistan, and aimed to identify potential inhibitors targeting AmpC beta‐lactamases. Methods A total of 17,500 clinical specimens were collected from June 2018 to June 2021 and analyzed
Muhammad Sarfraz   +10 more
wiley   +1 more source

Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam.

open access: yes, 2021
20.500.12530/87858Here, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam. The test performance was evaluated in a random selection of 160 previously molecularly characterized clinical ...
González-Bardanca, Mónica   +4 more
core   +1 more source

Relapsing Salmonella Meningitis in an Infant: A Case Report and Review of the Literature

open access: yesCase Reports in Pediatrics, Volume 2026, Issue 1, 2026.
Accurate diagnosis of bacterial meningitis is critical, particularly in young febrile infants. Although commercially available multiplex PCR assays enable rapid pathogen detection, these typically do not include Salmonella spp. or other Enterobacteriaceae, which may result in missed diagnoses and/or inappropriate treatment duration.
Sonia Alexiadou   +7 more
wiley   +1 more source

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study

open access: yes, 2023
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Ventero, Maria Paz   +8 more
core   +1 more source

Investigating the Effect of Xylitol on ompK36 Overexpression, Increased Meropenem Susceptibility, and Antibiofilm Activity in a Carbapenem‐Resistant Clinical Strain of Klebsiella pneumoniae

open access: yesInternational Journal of Microbiology, Volume 2026, Issue 1, 2026.
Carbapenem‐resistant Klebsiella pneumoniae poses a significant public health threat due to limited therapeutic options. This study investigated the potential of xylitol, a sugar alcohol, to enhance meropenem activity and combat biofilms in a clinical carbapenem‐resistant K. pneumoniae strain (Kp5) and a standard susceptible strain (K. pneumoniae subsp.
Omid Ahlelyorof   +5 more
wiley   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

open access: yesInternational Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi   +9 more
wiley   +1 more source

Mechanisms, Significance, Detection and Emerging Therapies for Carbapenem‐Resistant Enterobacterales: A Scoping Review

open access: yesJournal of Tropical Medicine, Volume 2026, Issue 1, 2026.
Background Carbapenems are among the most important broad‐spectrum β‐lactam antibiotics for the treatment of severe infections caused by multi–drug‐resistant Gram‐negative bacteria. However, the global emergence and dissemination of carbapenem‐resistant Enterobacterales (CRE), particularly carbapenemase‐producing Enterobacterales (CPE), have ...
Oluchi Judith Osuala   +8 more
wiley   +1 more source

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

open access: yes, 2017
Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and
Sibylle H. Lob   +6 more
core   +1 more source

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

open access: yes, 2018
Relebactam is a non-β-lactam, bicyclic diazabicyclooctane β-lactamase inhibitor of class A and class C β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs).
Sibylle H. Lob   +5 more
core   +1 more source

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

open access: yes
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Masahiro Suzuki   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy